Head of the Laboratory of Cell Technologies, Department of Experimental Medicine; Research Institute for Complex Issues of Cardiovascular Diseases, 6 Sosnovy Blvd, Kemerovo, 650002, Russia.
Junior Researcher, Laboratory of Cell Technologies, Department of Experimental Medicine; Research Institute for Complex Issues of Cardiovascular Diseases, 6 Sosnovy Blvd, Kemerovo, 650002, Russia.
Sovrem Tekhnologii Med. 2021;12(6):6-12. doi: 10.17691/stm2020.12.6.01. Epub 2020 Dec 28.
was to develop a technology for anti-thrombogenic drug coating of biodegradable porous scaffolds and to evaluate the physicomechanical and hemocompatible properties of functionally active vascular prostheses with and without a drug coating.
Vascular prostheses from polyhydroxybutyrate/valerate and polycaprolactone with the incorporated vascular endothelial growth factor, the main fibroblast growth factor, and the chemoattractant SDF-1α were made by emulsion electrospinning. Additional surface modification of the prostheses was carried out by forming a hydrogel coating of polyvinylpyrrolidone capable of binding drugs as a result of complexation. Unfractionated heparin and iloprost were used as anti-thrombogenic drugs.
We show that after the modification of vascular prostheses with heparin and iloprost, a 5.8-fold increase in the Young's modulus value was noted, which indicated a greater stiffness of these grafts compared to the unmodified controls. Platelet aggregation on the surface of heparin + iloprost coated vascular prostheses was 3.3 times less than that with the unmodified controls, and 1.8 times less compared to intact platelet-rich plasma. The surface of vascular prostheses with heparin and iloprost was resistant to adhesion of platelets and blood proteins.
Drug (unfractionated heparin and iloprost) coating of the surface of biodegradable prostheses significantly improved the anti-thrombogenic properties of these grafts but contributed to the increased stiffness of the prostheses.
开发一种可用于生物可降解多孔支架的抗血栓药物涂层技术，并评估具有和不具有药物涂层的功能性活性血管移植物的物理机械和血液相容性特性。
通过乳液静电纺丝制造了包含血管内皮生长因子、主要成纤维细胞生长因子和趋化因子 SDF-1α的聚羟基丁酸酯/戊酸酯和聚己内酯血管移植物。通过形成能够通过络合结合药物的聚乙烯基吡咯烷酮水凝胶涂层对移植物进行额外的表面改性。未分级肝素和伊洛前列素被用作抗血栓药物。
我们表明，在用肝素和伊洛前列素修饰血管移植物后，注意到杨氏模量值增加了 5.8 倍，这表明与未修饰的对照物相比，这些移植物的刚性更大。与未修饰的对照物相比，肝素+伊洛前列素涂层血管移植物表面的血小板聚集减少了 3.3 倍，与完整的富含血小板的血浆相比减少了 1.8 倍。肝素和伊洛前列素的表面抵抗血小板和血液蛋白的黏附。
在生物可降解移植物的表面进行药物（未分级肝素和伊洛前列素）涂层显著改善了这些移植物的抗血栓特性，但导致移植物的刚性增加。
